Skip to main content
Equibles

Christopher Simon

CEO

Haemonetics Corp (HAE)

Board Member

Haemonetics Corp (HAE)

Equibles does not estimate personal net worth.

Get an email with a short summary when Haemonetics Corp publishes a filing, an earnings call transcript or a press release.

Get HAE alerts

About Christopher Simon

Christopher Simon is recorded as Board Member at Haemonetics Corp (HAE) since January 1, 2016 and CEO at Haemonetics Corp (HAE). The proxy statement of Haemonetics Corp reports total compensation of $12,044,701 for Christopher Simon in fiscal 2026, including a base salary of $1,100,008. Disclosed compensation is on record for 9 fiscal years. Christopher Simon has spoken on 12 earnings calls across 1 company, most recently for Haemonetics Corp on May 7, 2026. Haemonetics Corp is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Haemonetics Corp includes Christopher A. Simon (CEO and Board Member), Ellen M. Zane (Chairman), James C. D'Arecca (CFO and Chief Accounting Officer) and 7 others.

Christopher Simon on recent calls

“We delivered fourth quarter revenue of $346 million, up 5% reported and 9% organic, ex-CSL, with adjusted EPS of $1.29, up 4% year-over-year.”
CEO, Haemonetics Corp Q4 FY2026 Earnings Call ·
“Second quarter revenue was $327 million and $649 million year-to-date, each reflecting a 5% reported revenue decline driven by $48 million and $101 million in last year's portfolio transitions, respectively.”
CEO, Haemonetics Corp Q2 FY2026 Earnings Call ·
“Today, we reported third quarter revenue of $349 million, growth of 4% on a reported basis and flat organically. Third quarter adjusted earnings per share were up 14% at $1.19.”
CEO, Haemonetics Corp Q3 FY2025 Earnings Call ·
“Today, we reported second quarter revenue of $346 million, growth of 9% on a reported basis and 4% organically, primarily driven by our hospital business. Year-to-date, revenue growth was 8% reported and 3% organic.”
CEO, Haemonetics Corp Q2 FY2025 Earnings Call ·
“Today, we reported organic revenue growth of 10% in the fourth quarter and 12% in fiscal year 2024. Adjusted earnings per diluted share was $0.90 in the quarter and $3.96 in the year, increases of 17% and 31% respectively.”
CEO, Haemonetics Corp Q4 FY2024 Earnings Call ·

Affiliation history

Company network

Leadership on record at Haemonetics Corp

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2026 Haemonetics Corp (HAE) $1,100,008 $12,044,701
2025 Haemonetics Corp (HAE) $1,100,000 $10,722,488
2024 Haemonetics Corp (HAE) $1,088,469 $11,545,113
2023 Haemonetics Corp (HAE) $1,012,885 $10,686,395
2022 Haemonetics Corp (HAE) $945,000 $8,702,220
2021 Haemonetics Corp (HAE) $963,173 $8,625,394
2020 Haemonetics Corp (HAE) $937,211 $9,398,204
2019 Haemonetics Corp (HAE) $893,954 $8,550,810
2018 Haemonetics Corp (HAE) $858,462 $7,851,310

Recent activity